“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer
EP. 1: Practical Management of Early Stage HER2+ Breast Cancer
ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute 
EP. 2: HER2-targeted Therapy: Routes of Administration
ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute 
EP. 3: FDA-approved Therapies for Relapsed/Refractory HER2+ mBC
ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute 
EP. 4: Management of Adverse Effects in R/R HER2+ mBC
ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute 